Seven Biopharma Firms on Beijing Stock Exchange Report Year-over-Year Growth in Revenue and Net Profit for First Three Quarters of 2024

　　【Pharmaceutical Network Industry DynamicsAccording to statistics, as of now, there are 21 biopharmaceutical companies listed on the Beijing Stock Exchange. Among these 21 companies, 18 reported revenues exceeding 100 million yuan in the first three quarters of 2024, with Jinbo leading at 988 million yuan in revenue. Overall, 10 companies saw year-on-year revenue growth in the first three quarters, and 8 companies experienced year-on-year growth in net profit attributable to shareholders. Notably, 7 companies achieved positive year-on-year growth in both revenue and net profit for the first three quarters, including Jinbo, Northland, Jiangsu Deyuan Pharmaceutical Co., Ltd., Chengdu Okay Pharmaceutical Co., Ltd., Sanyuan Gene, and Danna Biotech.
 

Specifically, Jinbo's Q3 2024 report shows that the company's main business revenue reached 988 million yuan, increasing by 91.16% year-on-year; the net profit attributable to shareholders was 520 million yuan, rising by 170.42% year-on-year; the non-recurring net profit was 511 million yuan, surging by 178.14% year-on-year. The report states that the growth in medical device revenue drove the increase in operating income. The company’s key medical device products are Class III implantable agents with Type A recombinant humanized collagen protein as the core ingredient.
 

Northland's report shows that the company's operating revenue in the first three quarters was 54.4508 million yuan, a year-on-year increase of 13.87%; the net profit attributable to parent company was -34.5949 million yuan, a year-on-year increase of 28.89%; the net profit excluding non-recurring gains and losses attributable to parent company was -40.9816 million yuan, a year-on-year increase of 18.89%. During the reporting period, the loss narrowed year on year, mainly due to investment income increasing by 540.44% over the previous period and accounts payable decreasing by 31.85% over the previous period. The company is professionally engaged in the research, production, and sales of genetically engineered protein drugs, gene therapy drugs, and ophthalmic drugs.
 

Jiangsu Deyuan Pharmaceutical Co., Ltd.'s Q3 2024 report shows that the company's revenue for the first three quarters was 653 million yuan, a year-on-year increase of 23.67%; the net profit attributable to parent company was 115 million yuan, a year-on-year increase of 36.43%; the non-recurring net profit attributable to parent company was 109 million yuan, a year-on-year increase of 48.65%. According to the announcement, the reason for the revenue growth in the first three quarters was mainly due to the increase in product sales gross margin from 79.85% in the same period last year to 81.93%. The company is a modern pharmaceutical enterprise specializing in the research, production, and sales of drugs for endocrine treatment, with products covering treatment areas such as diabetes, hypertension, peripheral neuropathy, overactive bladder, and rare diseases.
 

Chengdu Okay Pharmaceutical Co., Ltd.'s Q3 2024 report shows that the company achieved operating revenue of 224 million yuan in the first three quarters, representing a year-on-year increase of 31.8%; net profit attributable to parent company was 19.53 million yuan, increasing by 54.2% year-on-year; non-recurring net profit attributable to parent company amounted to 18.06 million yuan, surging by 65.5% year-on-year. The main reasons for the company's net profit growth in the first three quarters were the increase in sales revenue of its major products such as Diosmin and NHDC, as well as the rise in the comprehensive gross profit margin of the products.
 

Sanyuan Gene's disclosed Q3 2024 report shows that in the first three quarters of this year, the company's operating income reached 168 million yuan, a year-on-year increase of 10.50%; the net profit attributable to shareholders of the listed company was 11.8545 million yuan, a year-on-year increase of 8.33%. The announcement indicates that the performance growth is mainly due to the company’s sales team strengthening organizational development, actively exploring the market, improving market channel distribution, and achieving business growth. Meanwhile, the company has been actively promoting the construction of intelligent production and R&D base projects at the new plant area, as well as research projects such as the clinical trial for treating hepatitis B with a new PEG-integrated interferon mutant injection combined with genetic testing, further enhancing the company's operating performance.
 

Dana Biotech's Q3 2024 earnings report shows that in the first three quarters, operating revenue reached 176 million yuan, an increase of 0.91% year-over-year; net profit was 61.1088 million yuan, up by 6.23% year-over-year. The growth in performance was mainly driven by increased usage from existing customers, contributing to revenue growth, along with continuous income contributions from new customers. The growth in routine business reagents also boosted overall revenue and profit.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.